Oncaspar® (pegaspargase) is indicated as a component of a multi-agent
chemotherapeutic regimen for the first line treatment of patients with acute lymphoblastic
leukemia (ALL) and for the treatment of patients with ALL and hypersensitivity to
native forms of L-asparaginase.
Important Safety Information
Oncaspar® is contraindicated in patients with a history of serious
allergic reactions to Oncaspar®, and in patients with a history of
serious thrombosis, pancreatitis, or serious hemorrhagic events with prior L-asparaginase
Oncaspar® should be discontinued in the case of anaphylaxis or serious
allergic reactions, thrombosis, or pancreatitis. Glucose intolerance, in some cases
irreversible, can occur. Coagulopathy can occur. Perform appropriate monitoring.
The most common adverse reactions with Oncaspar® (≥2%) are allergic
reactions (including anaphylaxis), central nervous system (CNS) thrombosis, coagulopathy,
elevated transaminases, hyperbilirubinemia, hyperglycemia, and pancreatitis.
Please click here to review full Product Information.